var data={"title":"Primary humoral immunodeficiencies: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Primary humoral immunodeficiencies: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/contributors\" class=\"contributor contributor_credentials\">Francisco A Bonilla, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/contributors\" class=\"contributor contributor_credentials\">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/contributors\" class=\"contributor contributor_credentials\">Elizabeth TePas, MD, MS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 16, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;primary immunodeficiency disease&quot; denotes disorders resulting from the mostly inherited defects of the immune system. Multiple isolated defects and combined disorders have been described, including humoral immunodeficiencies, the severe combined immunodeficiencies, and disorders resulting from phagocytic and complement defects [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Additional categories of immunodeficiency include syndromic disorders, innate immune defects, disorders of immune dysregulation, autoinflammatory disorders, and somatic variants.</p><p>The symptoms, signs, and molecular pathophysiology of the major humoral immunodeficiencies will be reviewed here, as well as pertinent aspects of the laboratory evaluation and differential diagnosis. An overview of the laboratory abnormalities observed in the different primary humoral immunodeficiencies is presented in the table (<a href=\"image.htm?imageKey=ALLRG%2F105330\" class=\"graphic graphic_table graphicRef105330 \">table 1</a>). General considerations and descriptions of methods used in the evaluation of immune system function are discussed separately. (See <a href=\"topic.htm?path=laboratory-evaluation-of-the-immune-system\" class=\"medical medical_review\">&quot;Laboratory evaluation of the immune system&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PRESENTATION OF HUMORAL IMMUNODEFICIENCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Humoral immunodeficiency refers to diseases resulting from impaired antibody production because of either a molecular defect intrinsic to B cells or a failure of interactions between B and T cells [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/2\" class=\"abstract_t\">2</a>]. Cellular immunity is largely intact, in contrast to diseases classified as combined immunodeficiencies, despite underlying T cell defects in some of these diseases. (See <a href=\"topic.htm?path=combined-immunodeficiencies\" class=\"medical medical_review\">&quot;Combined immunodeficiencies&quot;</a> and <a href=\"topic.htm?path=severe-combined-immunodeficiency-scid-an-overview\" class=\"medical medical_review\">&quot;Severe combined immunodeficiency (SCID): An overview&quot;</a>.)</p><p>Antibody deficiency characteristically leads to recurrent, often severe, upper and lower respiratory tract infections with encapsulated bacteria (eg, <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>) [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/3\" class=\"abstract_t\">3</a>]. Children commonly present with recurrent otitis media, sinusitis, and pneumonia. The same is true of adults, although otitis media is less common. Viral infections of the respiratory and gastrointestinal tracts also occur with greater frequency and severity in these patients [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/4\" class=\"abstract_t\">4</a>]. Additional infectious diseases may be associated with particular syndromes. (See <a href=\"topic.htm?path=acute-otitis-media-in-children-epidemiology-microbiology-clinical-manifestations-and-complications#H4\" class=\"medical medical_review\">&quot;Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications&quot;, section on 'Risk factors'</a>.)</p><p>Common associated findings in children include poor growth and failure to thrive, recurrent fevers, and poor school attendance and performance [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/5\" class=\"abstract_t\">5</a>]. Chronic diarrhea is seen in both children and adults [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/6\" class=\"abstract_t\">6</a>]. Autoimmune disease is occasionally the presenting feature in adults. Primary humoral immunodeficiency should also be considered in patients with nodular lymphoid hyperplasia in the gut or unexplained hepatosplenomegaly.</p><p>Patients with suspected antibody deficiency should have measurement of total serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) (<a href=\"image.htm?imageKey=ALLRG%2F105330\" class=\"graphic graphic_table graphicRef105330 \">table 1</a>). The importance of immunoglobulin D (IgD), immunoglobulin E (IgE), and IgG subclass levels is controversial. (See <a href=\"#H11\" class=\"local\">'Other antibody defects'</a> below and <a href=\"topic.htm?path=laboratory-evaluation-of-the-immune-system\" class=\"medical medical_review\">&quot;Laboratory evaluation of the immune system&quot;</a>.)</p><p>Specific antibody titers to protein (eg, tetanus, diphtheria) and polysaccharide (eg, pneumococcal polysaccharides, <em>H. influenzae</em> type B capsular polysaccharide) antigens should also be measured (<a href=\"image.htm?imageKey=ALLRG%2F105330\" class=\"graphic graphic_table graphicRef105330 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/1,7\" class=\"abstract_t\">1,7</a>]. If specific antibody levels are low, booster immunization should be administered and titers measured again four weeks later. Isohemagglutinins may be measured in infants who have not completed a primary series of immunizations, since such antibodies are usually detectable by six months of age. (See <a href=\"topic.htm?path=assessing-the-immunologic-response-to-vaccination\" class=\"medical medical_review\">&quot;Assessing the immunologic response to vaccination&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21446846\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis for primary humoral immunodeficiencies includes both other primary immunodeficiencies as well as acquired forms of immunodeficiency.</p><p class=\"headingAnchor\" id=\"H276470510\"><span class=\"h2\">Combined immunodeficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Milder forms of combined T and B cell immunodeficiency can have a similar presentation to primary humoral immunodeficiencies. They can be distinguished from isolated antibody deficiencies by the presence of T cell defects. Combined immunodeficiencies are discussed in greater detail separately. (See <a href=\"topic.htm?path=combined-immunodeficiencies\" class=\"medical medical_review\">&quot;Combined immunodeficiencies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H276470516\"><span class=\"h2\">Protein-losing states</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protein-losing states such as protein-losing gastroenteropathy and nephrotic syndrome can lead to hypogammaglobulinemia and increased susceptibility to infection. These diseases are distinguished from primary humoral immunodeficiency by the presence of edema and decreased serum concentration of albumin. Protein-losing gastroenteropathy and nephrotic syndrome are discussed in greater detail separately. (See <a href=\"topic.htm?path=secondary-immunodeficiency-due-to-underlying-disease-states-environmental-exposures-and-miscellaneous-causes#H16802278\" class=\"medical medical_review\">&quot;Secondary immunodeficiency due to underlying disease states, environmental exposures, and miscellaneous causes&quot;, section on 'Disorders of protein loss'</a> and <a href=\"topic.htm?path=protein-losing-gastroenteropathy\" class=\"medical medical_review\">&quot;Protein-losing gastroenteropathy&quot;</a> and <a href=\"topic.htm?path=etiology-clinical-manifestations-and-diagnosis-of-nephrotic-syndrome-in-children\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H87306119\"><span class=\"h2\">Medications that cause hypogammaglobulinemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drugs that can cause hypogammaglobulinemia include gold, d-penicillamine, <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">sulfasalazine</a>, several anticonvulsants, and <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>. Glucocorticoids and other immunosuppressants (eg, thioguanines, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, calcineurin inhibitors) may also lead to secondary hypogammaglobulinemia. (See <a href=\"topic.htm?path=glucocorticoid-effects-on-the-immune-system\" class=\"medical medical_review\">&quot;Glucocorticoid effects on the immune system&quot;</a> and <a href=\"topic.htm?path=secondary-immunodeficiency-induced-by-biologic-therapies\" class=\"medical medical_review\">&quot;Secondary immunodeficiency induced by biologic therapies&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antirheumatic and anti-inflammatory drugs</strong> &ndash; Gold, d-penicillamine, and <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">sulfasalazine</a>, which are infrequently used in treating rheumatoid arthritis and other rheumatologic disorders, have been implicated in varying degrees of hypogammaglobulinemia [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/8-11\" class=\"abstract_t\">8-11</a>]. In one case caused by gold therapy, the immunoglobulin abnormalities appeared to be associated with a partial maturation blockade of B cells [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/9\" class=\"abstract_t\">9</a>]. In most cases, patients who develop this complication should be changed to a different therapy rather than treated with <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> replacement therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anticonvulsants</strong> &ndash; A number of anticonvulsants are associated with secondary hypogammaglobulinemia that involves decreases in either a single immunoglobulin class (eg, immunoglobulin A [IgA]) or panhypogammaglobulinemia. The mechanism is unknown. Reductions in immunoglobulins have been reported following both systemic hypersensitivity reactions to these agents and as an isolated adverse effect [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Most reports describe either individuals or small numbers of patients and have involved the following drugs: <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">levetiracetam</a>, valproic acid, <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a>, <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, and <a href=\"topic.htm?path=zonisamide-drug-information\" class=\"drug drug_general\">zonisamide</a> [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/12,14-20\" class=\"abstract_t\">12,14-20</a>]. It is generally recommended to switch to a different anticonvulsant rather than treat with <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> replacement therapy.</p><p/><p class=\"bulletIndent1\">In one case, the decrease in total immunoglobulins was associated with a diminished antibody response to vaccination with pneumococcal polysaccharides, and both defects resolved over a two-year period following discontinuation of drug (<a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">levetiracetam</a>) [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/15\" class=\"abstract_t\">15</a>]. In a second report, the serum immunoglobulin levels rose to normal within eight months of discontinuing the causative medication (<a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a>), although IgA levels remained below the reference interval [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a> &ndash; Rituximab can cause hypogammaglobulinemia, either transient or permanent, as discussed separately. (See <a href=\"topic.htm?path=secondary-immunodeficiency-induced-by-biologic-therapies#H447873800\" class=\"medical medical_review\">&quot;Secondary immunodeficiency induced by biologic therapies&quot;, section on 'Rituximab'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H625022001\"><span class=\"h2\">Other causes of acquired humoral immunodeficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other secondary states of impaired antibody production can result from medical conditions or infections that alter immune system function, environmental exposures such as radiation or toxic chemicals, or trauma. These causes of acquired humoral immunodeficiency are discussed in greater detail separately. (See <a href=\"topic.htm?path=secondary-immunodeficiency-due-to-underlying-disease-states-environmental-exposures-and-miscellaneous-causes\" class=\"medical medical_review\">&quot;Secondary immunodeficiency due to underlying disease states, environmental exposures, and miscellaneous causes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">X-LINKED AGAMMAGLOBULINEMIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>X-linked agammaglobulinemia (XLA or Bruton agammaglobulinemia) is due to a defect in Bruton's tyrosine kinase (Btk) that is expressed in B cells at all stages of development. Affected males with XLA generally experience recurrent bacterial infections of the respiratory tract (including otitis media, pneumonia, and sinusitis) initially occurring between 6 and 18 months of age. Enteroviruses, such as Coxsackievirus and ECHOvirus, are also problematic as humoral immunity is the primary defense against these viruses. Among patients with profound hypogammaglobulinemia, findings highly suggestive of XLA are normal T cell numbers and absent or low B cell numbers. Most patients with classical XLA have &lt;1 percent CD19 or CD20-positive lymphocytes. The treatment of choice is replacement therapy with <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>. XLA is discussed in detail elsewhere. (See <a href=\"topic.htm?path=agammaglobulinemia\" class=\"medical medical_review\">&quot;Agammaglobulinemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">AUTOSOMAL AGAMMAGLOBULINEMIAS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical and laboratory features of autosomal (recessive or dominant) forms of agammaglobulinemia are essentially identical to those of X-linked agammaglobulinemia (XLA) described above, except that either sex may be affected. These forms of agammaglobulinemia are reviewed elsewhere. (See <a href=\"topic.htm?path=agammaglobulinemia#H20\" class=\"medical medical_review\">&quot;Agammaglobulinemia&quot;, section on 'Autosomal-recessive agammaglobulinemia'</a> and <a href=\"topic.htm?path=agammaglobulinemia#H400036754\" class=\"medical medical_review\">&quot;Agammaglobulinemia&quot;, section on 'Autosomal-dominant agammaglobulinemia'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">HYPERIMMUNOGLOBULIN M SYNDROMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hyperimmunoglobulin M (HIGM) syndrome, also called &quot;immunodeficiency with normal or elevated immunoglobulin M (IgM),&quot; is a somewhat obsolete term denoting deficiency of immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin E (IgE), with normal or elevated serum concentrations of IgM due to class-switch recombination defects. Several gene defects have since been identified within this group of disorders (<a href=\"image.htm?imageKey=ALLRG%2F86094\" class=\"graphic graphic_table graphicRef86094 \">table 2</a>), and it is preferable to refer to the specific defect to avoid confusion. The clinical manifestations, diagnosis, and treatment of these syndromes are discussed in detail separately. (See <a href=\"topic.htm?path=hyperimmunoglobulin-m-syndromes\" class=\"medical medical_review\">&quot;Hyperimmunoglobulin M syndromes&quot;</a>.)</p><p>Three disorders have been reclassified as combined immunodeficiencies because of associated abnormalities of cellular immunity:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common defect is X-linked HIGM syndrome due to deficiency of CD40 ligand (CD40L, also called CD154, or TNFSF5 for tumor necrosis factor superfamily member 5). An autosomal recessive form due to deficiency of CD40 (TNFRSF5 or tumor necrosis family receptor superfamily member 5) is also recognized. (See <a href=\"topic.htm?path=hyperimmunoglobulin-m-syndromes\" class=\"medical medical_review\">&quot;Hyperimmunoglobulin M syndromes&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another disorder, termed nuclear factor-kappa-B essential modifier (NEMO) deficiency, is discussed separately. (See <a href=\"topic.htm?path=combined-immunodeficiencies#H18\" class=\"medical medical_review\">&quot;Combined immunodeficiencies&quot;, section on 'Defects of NF-kappa-B regulation'</a>.)</p><p/><p>Additional, rare forms of HIGM syndrome, with autosomal recessive inheritance in most cases and normal T cell function have been described. Some are caused by defects in enzymes required for the process of immunoglobulin class switching. Specifically, mutations in nucleic acid-modifying enzymes called activation-induced cytidine deaminase (AICDA or AID, MIM #605258) and uracil nucleoside glycosylase (UNG, MIM #608106) have been demonstrated. B cells cannot change isotype production from IgM to IgG, IgA, or IgE during antigen-dependent development and thus only produce appreciable quantities of IgM. (See <a href=\"topic.htm?path=hyperimmunoglobulin-m-syndromes\" class=\"medical medical_review\">&quot;Hyperimmunoglobulin M syndromes&quot;</a> and <a href=\"topic.htm?path=the-humoral-immune-response\" class=\"medical medical_review\">&quot;The humoral immune response&quot;</a> and <a href=\"topic.htm?path=normal-b-and-t-lymphocyte-development#H1230945\" class=\"medical medical_review\">&quot;Normal B and T lymphocyte development&quot;, section on 'Maturation of activated B cells'</a>.)</p><p>Other defects of class-switching due to impaired DNA-processing mechanisms include deficiencies of INO80 (a DNA helicase) [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/21\" class=\"abstract_t\">21</a>] and PMS2 and MSH6 (DNA mismatch repair endonucleases) [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Class-switching may also be impaired by defective costimulatory signals from T cells to B cells, as is seen with deficiency of inducible T cell costimulator (ICOS) [<a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">COMMON VARIABLE IMMUNODEFICIENCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common variable immunodeficiency is defined by low total serum concentrations of immunoglobulin G (IgG), as well as low immunoglobulin A (IgA) <span class=\"nowrap\">and/or</span> immunoglobulin M (IgM), poor or absent response to immunization, and characteristic clinical manifestations in the absence of any other detectable molecular defect (such as X-linked agammaglobulinemia [XLA] or hyperimmunoglobulin M [HIGM] syndrome and others). CD20, CD21, and CD81 deficiencies are rare types of common variable immunodeficiencies, and the list of single gene explanations for this phenotype is growing (<a href=\"image.htm?imageKey=ALLRG%2F107614\" class=\"graphic graphic_table graphicRef107614 \">table 3</a>). Common variable immunodeficiency is reviewed in detail elsewhere. (See <a href=\"topic.htm?path=clinical-manifestations-epidemiology-and-diagnosis-of-common-variable-immunodeficiency-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults&quot;</a> and <a href=\"topic.htm?path=pathogenesis-of-common-variable-immunodeficiency#H10\" class=\"medical medical_review\">&quot;Pathogenesis of common variable immunodeficiency&quot;, section on 'Genetics'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">TRANSIENT HYPOGAMMAGLOBULINEMIA OF INFANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Transient hypogammaglobulinemia of infancy (THI) is defined as an accentuation and prolongation of the &quot;physiologic&quot; hypogammaglobulinemia of infancy that is normally observed during the first three to six months of life (<a href=\"image.htm?imageKey=ALLRG%2F99496\" class=\"graphic graphic_figure graphicRef99496 \">figure 1</a>). The diagnosis is based upon immunoglobulin G (IgG) levels at least two standard deviations below the mean for aged-matched controls, with or without diminished values of other immunoglobulin isotypes, that remain low beyond six months of age and occur in the absence of other immunodeficiency conditions. THI rarely requires treatment with <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> replacement therapy. (See <a href=\"topic.htm?path=transient-hypogammaglobulinemia-of-infancy\" class=\"medical medical_review\">&quot;Transient hypogammaglobulinemia of infancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">OTHER ANTIBODY DEFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several other defects in antibody quantity or function have been identified. The classification of each of these conditions as immunodeficiencies is dependent upon a history of recurrent infections, autoimmune or gastrointestinal disorders, or other signs of impaired immune function since entirely asymptomatic individuals with each of these abnormalities have also been identified. Thus, these conditions do not represent immunodeficient states in all people.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">IgA deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunoglobulin A (IgA) deficiency is a relatively common immunologic variant that is asymptomatic in the majority of affected individuals. In a small minority, however, it can be associated with recurrent sinopulmonary and gastrointestinal infections, as well as autoimmune, gastrointestinal, and atopic disorders. IgA deficiency is reviewed separately. (See <a href=\"topic.htm?path=selective-iga-deficiency-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">&quot;Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Specific antibody deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Specific antibody deficiency (also referred to as polysaccharide nonresponsiveness, polysaccharide nonresponse, impaired polysaccharide responsiveness, or selective antibody deficiency with normal immunoglobulins) is a condition that may exist alone or as part of a more global immunodeficiency. It can be defined as unresponsiveness to polysaccharide antigens with all immunoglobulin isotype levels lying within their respective normal ranges. Symptomatic patients usually have recurrent bacterial sinopulmonary infections. (See <a href=\"topic.htm?path=specific-antibody-deficiency\" class=\"medical medical_review\">&quot;Specific antibody deficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">IgG subclass deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are four immunoglobulin G (IgG) subclasses: IgG1, IgG2, IgG3, and IgG4. IgG subclass deficiency is defined as the relative lack of one or more IgG subclasses, with a normal or near-normal concentration of total serum IgG in a patient with recurrent severe infections. Patients with IgG subclass deficiency rarely require treatment with <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> replacement therapy. These disorders are discussed in more detail separately. (See <a href=\"topic.htm?path=igg-subclass-deficiency\" class=\"medical medical_review\">&quot;IgG subclass deficiency&quot;</a> and <a href=\"topic.htm?path=igg-subclasses-physical-properties-genetics-and-biologic-functions\" class=\"medical medical_review\">&quot;IgG subclasses: Physical properties, genetics, and biologic functions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Selective IgM deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Selective deficiency of immunoglobulin M (sIgMD) is a rare immune disorder that has been reported in association with bacteremia and other serious infections. IgM levels are less than two standard deviations from the mean or less than 10 percent of the mean for age (more mildly decreased levels of IgM are generally not clinically significant). Patients with selective IgM deficiency may be asymptomatic, have repeated infections, <span class=\"nowrap\">and/or</span> present with associated conditions, such as autoimmune, malignant, and hematologic disorders or atopic diseases. (See <a href=\"topic.htm?path=selective-igm-deficiency\" class=\"medical medical_review\">&quot;Selective IgM deficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Selective IgE deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Selective immunoglobulin E (IgE) deficiency is defined as a level of IgE &lt;2.5 international <span class=\"nowrap\">units/mL</span> in a patient whose other immunoglobulin levels and IgG subclass levels are normal. It is a laboratory finding that does not necessarily equate to a clinical disorder. (See <a href=\"topic.htm?path=selective-ige-deficiency\" class=\"medical medical_review\">&quot;Selective IgE deficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1492365312\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-primary-immunodeficiencies\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Primary immunodeficiencies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14368569\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Humoral immunodeficiency refers to diseases resulting from impaired antibody production because of either a molecular defect intrinsic to B cells or a failure of interactions between B and T cells. (See <a href=\"#H2\" class=\"local\">'Presentation of humoral immunodeficiency'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibody deficiency characteristically leads to recurrent, often severe, upper and lower respiratory tract infections with encapsulated bacteria (eg, <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>). (See <a href=\"#H2\" class=\"local\">'Presentation of humoral immunodeficiency'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Findings associated with severe primary humoral immunodeficiencies include failure to thrive, chronic diarrhea, recurrent fever, nodular lymphoid hyperplasia in the gut, and hepatosplenomegaly. (See <a href=\"#H2\" class=\"local\">'Presentation of humoral immunodeficiency'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation of suspected primary humoral immunodeficiency includes quantitative immunoglobulin levels, specific antibody titers, and enumeration of B cells and B cell subpopulations. (See <a href=\"topic.htm?path=assessing-the-immunologic-response-to-vaccination\" class=\"medical medical_review\">&quot;Assessing the immunologic response to vaccination&quot;</a> and <a href=\"topic.htm?path=laboratory-evaluation-of-the-immune-system\" class=\"medical medical_review\">&quot;Laboratory evaluation of the immune system&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1682621188\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge E Richard Stiehm, MD, who contributed as a Section Editor to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/1\" class=\"nounderline abstract_t\">Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/2\" class=\"nounderline abstract_t\">Notarangelo L, Casanova JL, Fischer A, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 2004; 114:677.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/3\" class=\"nounderline abstract_t\">Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 2002; 109:581.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/4\" class=\"nounderline abstract_t\">Kainulainen L, Vuorinen T, Rantakokko-Jalava K, et al. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 2010; 126:120.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/5\" class=\"nounderline abstract_t\">Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007; 149:410.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/6\" class=\"nounderline abstract_t\">Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124:658.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/7\" class=\"nounderline abstract_t\">Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2012; 130:S1.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/8\" class=\"nounderline abstract_t\">Farr M, Struthers GR, Scott DG, Bacon PA. Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis. Br J Rheumatol 1985; 24:367.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/9\" class=\"nounderline abstract_t\">Guillemin F, Bene MC, Aussedat R, et al. Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells. J Rheumatol 1987; 14:1034.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/10\" class=\"nounderline abstract_t\">Lee AH, Levinson AI, Schumacher HR Jr. Hypogammaglobulinemia and rheumatic disease. Semin Arthritis Rheum 1993; 22:252.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/11\" class=\"nounderline abstract_t\">Williams A, Scott DL, Greenwood A, Huskisson EC. The clinical value of measuring immunoglobulins when assessing penicillamine therapy in rheumatoid arthritis. Clin Rheumatol 1988; 7:347.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/12\" class=\"nounderline abstract_t\">Knight AK, Cunningham-Rundles C. Oxcarbazepine-induced immunoglobulin deficiency. Clin Diagn Lab Immunol 2005; 12:560.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/13\" class=\"nounderline abstract_t\">Okumura A, Tsuge I, Kamachi Y, et al. Transient hypogammaglobulinemia after antiepileptic drug hypersensitivity. Pediatr Neurol 2007; 36:342.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/14\" class=\"nounderline abstract_t\">Abe S, Suzuki T, Hori T, et al. Hypogammaglobulinemia during antipsychotic therapy. Psychiatry Clin Neurosci 1998; 52:115.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/15\" class=\"nounderline abstract_t\">Azar AE, Ballas ZK. Reversible panhypogammaglobulinemia associated with the antiepileptic agent levetiracetam. Ann Allergy Asthma Immunol 2008; 101:108.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/16\" class=\"nounderline abstract_t\">Hayman G, Bansal A. Antibody deficiency associated with carbamazepine. BMJ 2002; 325:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/17\" class=\"nounderline abstract_t\">Joubert PH, Aucamp AK, Potgieter GM, Verster F. Epilepsy and IgA deficiency--the effect of sodium valproate. S Afr Med J 1977; 52:642.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/18\" class=\"nounderline abstract_t\">Maeoka Y, Hara T, Dejima S, Takeshita K. IgA and IgG2 deficiency associated with zonisamide therapy: a case report. Epilepsia 1997; 38:611.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/19\" class=\"nounderline abstract_t\">Pereira LF, Sanchez JF. Reversible panhypogammaglobulinemia associated with phenytoin treatment. Scand J Infect Dis 2002; 34:785.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/20\" class=\"nounderline abstract_t\">Rice CM, Johnston SL, Unsworth DJ, et al. Recurrent herpes simplex virus encephalitis secondary to carbamazepine induced hypogammaglobulinaemia. J Neurol Neurosurg Psychiatry 2007; 78:1011.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/21\" class=\"nounderline abstract_t\">Kracker S, Curtis J, Ibrahim MA, et al. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase &delta; syndrome. J Allergy Clin Immunol 2014; 134:233.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/22\" class=\"nounderline abstract_t\">P&eacute;ron S, Metin A, Gard&egrave;s P, et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 2008; 205:2465.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/23\" class=\"nounderline abstract_t\">Gard&egrave;s P, Forveille M, Alyanakian MA, et al. Human MSH6 deficiency is associated with impaired antibody maturation. J Immunol 2012; 188:2023.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-humoral-immunodeficiencies-an-overview/abstract/24\" class=\"nounderline abstract_t\">Warnatz K, Bossaller L, Salzer U, et al. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006; 107:3045.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3914 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14368569\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PRESENTATION OF HUMORAL IMMUNODEFICIENCY</a></li><li><a href=\"#H21446846\" id=\"outline-link-H21446846\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H276470510\" id=\"outline-link-H276470510\">Combined immunodeficiency</a></li><li><a href=\"#H276470516\" id=\"outline-link-H276470516\">Protein-losing states</a></li><li><a href=\"#H87306119\" id=\"outline-link-H87306119\">Medications that cause hypogammaglobulinemia</a></li><li><a href=\"#H625022001\" id=\"outline-link-H625022001\">Other causes of acquired humoral immunodeficiency</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">X-LINKED AGAMMAGLOBULINEMIA</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">AUTOSOMAL AGAMMAGLOBULINEMIAS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">HYPERIMMUNOGLOBULIN M SYNDROMES</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">COMMON VARIABLE IMMUNODEFICIENCY</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">TRANSIENT HYPOGAMMAGLOBULINEMIA OF INFANCY</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">OTHER ANTIBODY DEFECTS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">IgA deficiency</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Specific antibody deficiency</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">IgG subclass deficiency</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Selective IgM deficiency</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Selective IgE deficiency</a></li></ul></li><li><a href=\"#H1492365312\" id=\"outline-link-H1492365312\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H14368569\" id=\"outline-link-H14368569\">SUMMARY</a></li><li><a href=\"#H1682621188\" id=\"outline-link-H1682621188\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ALLRG/3914|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/99496\" class=\"graphic graphic_figure\">- Immunoglobulin levels in the fetus and infant in the first year</a></li></ul></li><li><div id=\"ALLRG/3914|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/105330\" class=\"graphic graphic_table\">- Laboratory findings in antibody deficiencies</a></li><li><a href=\"image.htm?imageKey=ALLRG/86094\" class=\"graphic graphic_table\">- Features of genetically determined hyper-IgM syndrome</a></li><li><a href=\"image.htm?imageKey=ALLRG/107614\" class=\"graphic graphic_table\">- Genetic defects causing CVID phenotypes</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-otitis-media-in-children-epidemiology-microbiology-clinical-manifestations-and-complications\" class=\"medical medical_review\">Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=agammaglobulinemia\" class=\"medical medical_review\">Agammaglobulinemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=assessing-the-immunologic-response-to-vaccination\" class=\"medical medical_review\">Assessing the immunologic response to vaccination</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-epidemiology-and-diagnosis-of-common-variable-immunodeficiency-in-adults\" class=\"medical medical_review\">Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=combined-immunodeficiencies\" class=\"medical medical_review\">Combined immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-manifestations-and-diagnosis-of-nephrotic-syndrome-in-children\" class=\"medical medical_review\">Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucocorticoid-effects-on-the-immune-system\" class=\"medical medical_review\">Glucocorticoid effects on the immune system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hyperimmunoglobulin-m-syndromes\" class=\"medical medical_review\">Hyperimmunoglobulin M syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=igg-subclass-deficiency\" class=\"medical medical_review\">IgG subclass deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=igg-subclasses-physical-properties-genetics-and-biologic-functions\" class=\"medical medical_review\">IgG subclasses: Physical properties, genetics, and biologic functions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=laboratory-evaluation-of-the-immune-system\" class=\"medical medical_review\">Laboratory evaluation of the immune system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=normal-b-and-t-lymphocyte-development\" class=\"medical medical_review\">Normal B and T lymphocyte development</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-common-variable-immunodeficiency\" class=\"medical medical_review\">Pathogenesis of common variable immunodeficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=protein-losing-gastroenteropathy\" class=\"medical medical_review\">Protein-losing gastroenteropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=secondary-immunodeficiency-due-to-underlying-disease-states-environmental-exposures-and-miscellaneous-causes\" class=\"medical medical_review\">Secondary immunodeficiency due to underlying disease states, environmental exposures, and miscellaneous causes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=secondary-immunodeficiency-induced-by-biologic-therapies\" class=\"medical medical_review\">Secondary immunodeficiency induced by biologic therapies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-iga-deficiency-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-ige-deficiency\" class=\"medical medical_review\">Selective IgE deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-igm-deficiency\" class=\"medical medical_review\">Selective IgM deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=severe-combined-immunodeficiency-scid-an-overview\" class=\"medical medical_review\">Severe combined immunodeficiency (SCID): An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-primary-immunodeficiencies\" class=\"medical medical_society_guidelines\">Society guideline links: Primary immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=specific-antibody-deficiency\" class=\"medical medical_review\">Specific antibody deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-humoral-immune-response\" class=\"medical medical_review\">The humoral immune response</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transient-hypogammaglobulinemia-of-infancy\" class=\"medical medical_review\">Transient hypogammaglobulinemia of infancy</a></li></ul></div></div>","javascript":null}